Francesco Grigioni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4678067/publications.pdf

Version: 2024-02-01

١			76326	53230
	161	7,790	40	85
	papers	citations	h-index	g-index
	170	170	170	7916
	all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients. Journal of Cardiovascular Medicine, 2022, 23, 135-140.	1.5	2
2	Impact of Mediterranean diet on metabolic and inflammatory status of patients with polyvascular atherosclerotic disease. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 117-124.	2.6	6
3	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. American Journal of Cardiovascular Drugs, 2022, 22, 263-270.	2.2	7
4	Pressure–volume relationship by pharmacological stress cardiovascular magnetic resonance. International Journal of Cardiovascular Imaging, 2022, 38, 853-861.	1.5	0
5	Association of transcatheter edge-to-edge repair with improved survival in older patients with severe, symptomatic degenerative mitral regurgitation. European Heart Journal, 2022, 43, 1626-1635.	2.2	22
6	Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 512.	2.4	3
7	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 1086-1094.	1.7	1
8	New Guideline-Directed Treatments for Heart Failure. JACC: Case Reports, 2022, 4, 75-78.	0.6	3
9	In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life, 2022, 12, 393.	2.4	27
10	Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index. Heart and Vessels, 2022, 37, 1471-1477.	1.2	1
11	The Role of Angiogenesis and Arteriogenesis in Myocardial Infarction and Coronary Revascularization. Journal of Cardiovascular Translational Research, 2022, 15, 1024-1048.	2.4	9
12	Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status. American Journal of Cardiology, 2022, 171, 49-54.	1.6	1
13	Invasive Assessment of Coronary Microvascular Function. Journal of Clinical Medicine, 2022, 11, 228.	2.4	17
14	Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0
15	Novel Computed Tomography Variables for Assessing Tricuspid Valve Morphology: Results from the TRIMA (Tricuspid Regurgitation IMAging) Study. Journal of Clinical Medicine, 2022, 11, 2825.	2.4	7
16	Antithrombotic treatment for valve prostheses: Which drug, which dose, and when?. Progress in Cardiovascular Diseases, 2022, 72, 4-14.	3.1	4
17	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences, 2022, 23, 7261.	4.1	4
18	Clinical impact of defibrillation testing in a realâ€world Sâ€ICD population: Data from the ELISIR registry. Journal of Cardiovascular Electrophysiology, 2021, 32, 468-476.	1.7	10

#	Article	IF	CITATIONS
19	Non-INvasive Functional and Anatomic vascular evaluation for the prediction of coronary artery disease: The NINFA study. International Journal of Cardiology, 2021, 322, 16-22.	1.7	3
20	Current management and prognosis of patients with recurrent myocardial infarction. Reviews in Cardiovascular Medicine, 2021, 22, 731.	1.4	3
21	Prediction of 5-Year Mortality in Patients with Chronic Coronary Syndrome Treated with Elective Percutaneous Coronary Intervention: Role of the ACEF Score. Journal of Cardiovascular Translational Research, 2021, 14, 1125-1130.	2.4	2
22	Ischemic Mitral Regurgitation: A Multifaceted Syndrome with Evolving Therapies. Biomedicines, 2021, 9, 447.	3.2	4
23	Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2021, 14, 1085-1092.	2.4	2
24	Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity. Endocrine, 2021, 73, 339-346.	2.3	8
25	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Frontiers in Pharmacology, 2021, 12, 670155.	3.5	27
26	Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19: a systematic review and meta-analysis. Internal and Emergency Medicine, 2021, 16, 1975-1985.	2.0	6
27	Functional Mitral Regurgitation Outcome and Grading in HeartÂFailure With Reduced Ejection Fraction. JACC: Cardiovascular Imaging, 2021, 14, 2303-2315.	5. 3	34
28	The Central Role of Left Atrium in Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 704762.	2.4	13
29	Functional mitral regurgitation: a proportionate or disproportionate focus of attention?. European Journal of Heart Failure, 2021, 23, 1759-1762.	7.1	3
30	Usefulness of Adding Pre-procedural Glycemia to the Mehran Score to Enhance Its Ability to Predict Contrast-induced Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention Development and Validation of a Predictive Model. American Journal of Cardiology, 2021, 155, 16-22.	1.6	10
31	Advanced Heart Failure: From Pathophysiology to Clinical Management. Heart Failure Clinics, 2021, 17, i.	2.1	0
32	Management of Advanced Heart Failure: The Science of Uncertainty and the Art of Probability. Heart Failure Clinics, 2021, 17, xv-xvi.	2.1	0
33	Mitral and Tricuspid Valves Percutaneous Repair in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 607-618.	2.1	9
34	Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril–valsartan: does money matter?. European Journal of Preventive Cardiology, 2021, 28, 1670-1672.	1.8	4
35	Transcatheter Tricuspid Valve Therapy: From Anatomy to Intervention. Frontiers in Cardiovascular Medicine, 2021, 8, 778445.	2.4	12
36	Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study. Journal of Diabetes Research, 2021, 2021, 1-9.	2.3	3

#	Article	IF	CITATIONS
37	730 Prediction of type 4a myocardial infarction with the angiography-derived haemodynamic (added) index. European Heart Journal Supplements, 2021, 23, .	0.1	O
38	The Pivotal Role of Invasive Functional Assessment in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA). Frontiers in Cardiovascular Medicine, 2021, 8, 781485.	2.4	7
39	Current diagnostic ECG criteria for left ventricular hypertrophy: is it time to change paradigm in the analysis of data?. Journal of Cardiovascular Medicine, 2020, 21, 128-133.	1.5	11
40	Characterization of inflammatory profile by breath analysis in chronic coronary syndromes. Journal of Cardiovascular Medicine, 2020, 21, 675-681.	1.5	3
41	Chemoreceptor hyperactivity in heart failure: Is lactate the culprit?. European Journal of Preventive Cardiology, 2020, 28, e8-e10.	1.8	2
42	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3075-e3089.	3.6	11
43	Non-vitamin K oral anticoagulants at the time of cardiac rhythm device surgery: A systematic review and meta-analysis. Thrombosis Research, 2020, 188, 90-96.	1.7	7
44	Antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty: rational convincement and supporting evidence. European Journal of Internal Medicine, 2020, 77, 44-51.	2,2	3
45	LVAD and functional capacity: Do we know how it works and what to do?. European Journal of Preventive Cardiology, 2019, 26, 1803-1805.	1.8	0
46	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
47	Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 264-274.	2.8	54
48	Aortic Valve Surgery in Nonelderly Patients: Insights Gained From AVIATOR. Seminars in Thoracic and Cardiovascular Surgery, 2019, 31, 643-649.	0.6	10
49	Treatment of Functional Mitral Regurgitation. Circulation, 2019, 139, 2289-2291.	1.6	14
50	Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. Cardiovascular Diabetology, 2019, 18, 147.	6.8	29
51	AVIATOR: An open international registry to evaluate medical and surgical outcomes of aortic valve insufficiency and ascending aorta aneurysm. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2202-2211.e7.	0.8	31
52	Interactions between Atrial Fibrillation, Cardiovascular Risk Factors, and ApoE Genotype in Promoting Cognitive Decline in Patients with Alzheimer's Disease: A Prospective Cohort Study. Journal of Alzheimer's Disease, 2018, 62, 713-725.	2.6	25
53	The MIDA Mortality Risk Score: development and external validation of a prognostic model for early and late death in degenerative mitral regurgitation. European Heart Journal, 2018, 39, 1281-1291.	2.2	54
54	Predicting device failure after percutaneous repair of functional mitral regurgitation in advanced heart failure: Implications for patient selection. International Journal of Cardiology, 2018, 257, 182-187.	1.7	26

#	Article	IF	Citations
55	Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection. Journal of Clinical Microbiology, 2018, 56, .	3.9	32
56	Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients. Transplantation, 2018, 102, 493-501.	1.0	28
57	Cancer Therapy-Related Cardiac Dysfunction: Are We Treating Echocardiograms, Patients, Neither, or Both?. Chemotherapy, 2018, 63, 338-339.	1.6	1
58	Speckle tracking for the diagnosis of subclinical myocardial involvement in systemic sclerosis: A mandatory tool for everyday clinical practice?. European Journal of Preventive Cardiology, 2018, 25, 1596-1597.	1.8	3
59	Calculation of the ALMA Risk of Right Ventricular Failure After Left Ventricular Assist Device Implantation. ASAIO Journal, 2018, 64, e140-e147.	1.6	22
60	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. Journal of Clinical Investigation, 2018, 128, 3490-3503.	8.2	31
61	Tricuspid regurgitation: what is the real clinical impact and how often should it be treated?. EuroIntervention, 2018, 14, AB101-AB111.	3.2	35
62	Multimodality imaging of the tricuspid valve with implication for percutaneous repair approaches. Heart, 2017, 103, 1073-1081.	2.9	52
63	Twenty-Year Outcome After Mitral Repair Versus Replacement for Severe Degenerative Mitral Regurgitation. Circulation, 2017, 135, 410-422.	1.6	238
64	Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes. Journal of Heart and Lung Transplantation, 2017, 36, 1217-1225.	0.6	66
65	Post-operative pleural effusion in a heart transplant recipient: A single-case study of physiotherapy treatment. International Journal of Therapy and Rehabilitation, 2017, 24, 302-305.	0.3	4
66	The risk of right ventricular failure with current continuous-flow left ventricular assist devices. Expert Review of Medical Devices, 2017, 14, 969-983.	2.8	13
67	Outcomes in Degenerative Mitral Regurgitation: Current State-of-the Art and Future Directions. Progress in Cardiovascular Diseases, 2017, 60, 370-385.	3.1	21
68	Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy The paradigm shift has already happened: Is it time to wake up and realise it?. European Journal of Preventive Cardiology, 2017, 24, 1381-1382.	1.8	0
69	Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure?. International Journal of Cardiology, 2017, 228, 191-197.	1.7	40
70	Nonobstructive Versus Obstructive Coronary Artery Disease in Acute Coronary Syndrome: A Metaâ€Analysis. Journal of the American Heart Association, 2016, 5, .	3.7	87
71	Current Perspectives on Cytomegalovirus in Heart Transplantation. Current Transplantation Reports, 2016, 3, 358-366.	2.0	0
72	Role of Intraâ€Aortic Balloon Pump and Extracorporeal Membrane Oxygenation in Early Graft Failure After Cardiac Transplantation. Artificial Organs, 2016, 40, E136-45.	1.9	17

#	Article	IF	CITATIONS
73	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, $2016, 9, .$	3.9	103
74	Clinical Management of Transplant Recipients. , 2016, , 171-184.		0
75	The Pilot European Survey of Atrial Fibrillation: how to look at heart failure through a keyhole. European Journal of Heart Failure, 2015, 17, 541-543.	7.1	1
76	Acute heart failure in patients with acute aortic syndrome: pathophysiology and clinical–prognostic implications. European Journal of Heart Failure, 2015, 17, 917-924.	7.1	9
77	Clinical Use of Doppler Echocardiography in Organic Mitral Regurgitation: From Diagnosis to Patients' Management. Journal of Cardiovascular Imaging, 2015, 23, 121.	0.8	4
78	ASSESSMENT OF MITRAL REGURGITATION THROUGH DOPPLER ECHOCARDIOGRAPHY: FEASIBILITY, PITFALLS AND DIAGNOSTIC ADVANTAGES. Journal of Mechanics in Medicine and Biology, 2015, 15, 1540011.	0.7	0
79	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1146-1153.	0.6	45
80	RotaFlow and CentriMag Extracorporeal Membrane Oxygenation Support Systems as Treatment Strategies for Refractory Cardiogenic Shock. Journal of Cardiac Surgery, 2015, 30, 201-208.	0.7	8
81	First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2015, 8, e211-e214.	2.9	111
82	Clinical Prognostic Value of Secondary Mitral Valve Regurgitation. , 2015, , 13-18.		0
83	Use of Mechanical Circulatory Support Devices in End-Stage Heart Failure Patients. Journal of Cardiac Surgery, 2014, 29, 717-722.	0.7	5
84	Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation Due to Flail Mitral Valve Leaflets. Survey of Anesthesiology, 2014, 58, 271-272.	0.1	5
85	Long-Term Mortality Associated With Left Ventricular Dysfunction in Mitral Regurgitation Due to Flail Leaflets. Circulation: Cardiovascular Imaging, 2014, 7, 363-370.	2.6	47
86	Comparative effectiveness of disease-modifying-drugs in elderly patients after incident hospitalization for heart failure. International Journal of Cardiology, 2014, 173, 557-560.	1.7	1
87	Prognostic stratification and treatment of cardiac light chain amyloidosis: A narrow path in the jungle. Journal of Heart and Lung Transplantation, 2014, 33, 136-138.	0.6	3
88	Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Treatment Strategies and Analysis of Risk Factors. Artificial Organs, 2014, 38, E129-41.	1.9	74
89	Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation Due to Flail Mitral Valve Leaflets. JAMA - Journal of the American Medical Association, 2013, 310, 609.	7.4	315
90	Implantation of cardioverter-defibrillator: Effects on shoulder function. International Journal of Cardiology, 2013, 168, 294-299.	1.7	18

#	Article	IF	Citations
91	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	2.2	252
92	Impact of ageing on presentation and outcome of mitral regurgitation due to flail leaflet: a multicentre international study. European Heart Journal, 2013, 34, 2600-2609.	2.2	27
93	EUR <i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	7.1	645
94	Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice. American Journal of Transplantation, 2013, 13, 1217-1226.	4.7	62
95	Calf cramps in a heart transplant patient during the postoperative course: a case report. International Journal of Therapy and Rehabilitation, 2013, 20, 55-57.	0.3	2
96	Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies. Journal of Transplantation, 2013, 2013, 1-6.	0.5	13
97	Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study. Journal of Heart and Lung Transplantation, 2012, 31, 565-570.	0.6	56
98	Defining the Diagnosis in Echocardiographically Suspected Senile Systemic Amyloidosis. JACC: Cardiovascular Imaging, 2012, 5, 755-758.	5.3	33
99	Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: A Multicenter Long-term International Study. European Heart Journal, 2011, 32, 751-759.	2.2	158
100	Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. Journal of Heart and Lung Transplantation, 2011, 30, 1305-1311.	0.6	20
101	Quantitation of Mitral Regurgitation. Seminars in Thoracic and Cardiovascular Surgery, 2011, 23, 106-114.	0.6	10
102	Changes in exercise capacity induced by heart transplantation: prognostic and therapeutic implications. Scandinavian Journal of Medicine and Science in Sports, 2011, 21, 519-525.	2.9	8
103	Left Atrial Size Is a Potent Predictor of Mortality in Mitral Regurgitation Due to Flail Leaflets. Circulation: Cardiovascular Imaging, 2011, 4, 473-481.	2.6	113
104	Cyclosporine Lowering With Everolimus or Mycophenolate to Preserve Renal Function in Heart Recipients: A Randomized Study. Transplantation, 2010, 89, 263-265.	1.0	29
105	Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a longâ€ŧerm outcome study. European Journal of Heart Failure, 2010, 12, 382-388.	7.1	130
106	Management of asymptomatic mitral regurgitation. Heart, 2010, 96, 1938-1945.	2.9	8
107	Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction. American Heart Journal, 2010, 160, S16-S21.	2.7	12
108	Heart transplantation in infants with idiopathic hypertrophic cardiomyopathy. Pediatric Transplantation, 2009, 13, 650-653.	1.0	9

#	Article	IF	Citations
109	Prophylaxis Versus Preemptive Anti-cytomegalovirus Approach for Prevention of Allograft Vasculopathy in Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2009, 28, 461-467.	0.6	83
110	Survival Implication of Left Ventricular End-Systolic Diameter in Mitral Regurgitation Due to Flail Leaflets. Journal of the American College of Cardiology, 2009, 54, 1961-1968.	2.8	221
111	Prophylaxis Versus Preemptive Therapy for Prevention of the Consequences of Cytomegalovirus Infection in Transplant Recipients: A Still Unresolved Issue. Transplantation, 2009, 87, 305-306.	1.0	6
112	Age and heart transplantation: results from a heart failure management unit. Clinical Transplantation, 2008, 22, 150-155.	1.6	3
113	Heart Transplantation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 387-392.	1.6	70
114	Thromboembolic Complications After Surgical Correction of Mitral Regurgitation. Journal of the American College of Cardiology, 2008, 51, 1203-1211.	2.8	124
115	Outcomes in Mitral Regurgitation Due to Flail Leaflets. JACC: Cardiovascular Imaging, 2008, 1, 133-141.	5. 3	157
116	Safety and Efficacy of Ezetimibe With Low Doses of Simvastatin in Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2008, 27, 685-688.	0.6	18
117	Cardiac Transplantation From a Carbon Monoxide Intoxicated Donor. Transplantation Proceedings, 2008, 40, 1563-1565.	0.6	13
118	Letter by Boriani et al Regarding Article, "Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Study― Circulation, 2008, 118, e515; author reply e516.	1.6	0
119	Clinical Outcome After Surgical Correction of Mitral Regurgitation Due to Papillary Muscle Rupture. Circulation, 2008, 118, 1528-1534.	1.6	134
120	Long-Term Effect of Folic Acid Therapy in Heart Transplant Recipients: Follow-Up Analysis of a Randomized Study. Transplantation, 2008, 85, 1146-1150.	1.0	7
121	Sex Differences in Morphology and Outcomes of Mitral Valve Prolapse. Annals of Internal Medicine, 2008, 149, 787.	3.9	140
122	Diagnosis of idiopathic restrictive cardiomyopathy at a glance. Journal of Cardiovascular Medicine, 2007, 8, 758.	1.5	1
123	Intraoperative Rupture of the Donor Aorta During Heart Transplantation: Surgical Management With a Bentall-de Bono Procedure. Transplantation Proceedings, 2007, 39, 1573-1574.	0.6	2
124	Prevalence of Substance-Related Disorders in Heart Transplantation Candidates. Transplantation Proceedings, 2007, 39, 1970-1972.	0.6	12
125	Potential of Medical Treatment, Device Therapy, and Conventional Surgery in Patients Referred for Heart Transplantation. Journal of Cardiac Surgery, 2007, 22, 456-458.	0.7	0
126	Cardiac resynchronization therapy in clinical practice: Need for electrical, mechanical, clinical and logistic synchronization. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 215-224.	1.3	16

#	Article	IF	CITATIONS
127	Static and Dynamic Predictors of Adverse Events in Patients with Intermediate Cardiopulmonary Capacity Referred for Heart Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 85-89.	0.6	2
128	Prognostic Stratification of Women With Chronic Heart Failure Referred for Heart Transplantation: Relevance of Gender as Compared With Gender-related Characteristics. Journal of Heart and Lung Transplantation, 2006, 25, 648-652.	0.6	7
129	Prognostic Implications of Serial Assessments of Pulmonary Hypertension in Severe Chronic Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 1241-1246.	0.6	155
130	Electrocardiographic remodeling during cardiac resynchronization therapy. International Journal of Cardiology, 2006, 108, 165-170.	1.7	29
131	Acute and chronic haemodynamic effects of biventricular pacing and of switching to different pacing modalities in heart failure patients. International Journal of Cardiology, 2006, 110, 318-323.	1.7	14
132	Long-Term Safety and Effectiveness of Statins for Heart Transplant Recipients in Routine Clinical Practice. Transplantation Proceedings, 2006, 38, 1507-1510.	0.6	27
133	Role of severe functional mitral regurgitation in predicting electrical remodeling in idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 691-695.	1.5	0
134	Relevance of cardioverter defibrillators for the prevention of sudden cardiac death on the timing of heart transplantation. Clinical Transplantation, 2006, 20, 684-688.	1.6	8
135	Unusual Rapid Evolution of Type B Aortic Dissection in a Marfan Patient Following Heart Transplantation: Successful Endovascular Treatment. European Journal of Vascular and Endovascular Surgery, 2006, 32, 358-360.	1.5	17
136	Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 143-153.	3.0	57
137	Homocysteine-Lowering Therapy and Early Progression of Transplant Vasculopathy: A Prospective, Randomized, IVUS-Based Study. American Journal of Transplantation, 2005, 5, 2258-2264.	4.7	16
138	Safety and Efficacy of Two Types of Influenza Vaccination in Heart Transplant Recipients: A Prospective Randomised Controlled Study. Journal of Heart and Lung Transplantation, 2005, 24, 588-592.	0.6	69
139	Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 260-267.	2.8	236
140	Relationship between psychiatric disorders and physical status during the course of a heart transplantation program: a prospective, longitudinal study. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 900-3.	0.1	1
141	Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells. Circulation, 2004, 109, 532-536.	1.6	85
142	Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. American Journal of Cardiology, 2004, 93, 371-373.	1.6	14
143	Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplantation Proceedings, 2004, 36, 645-647.	0.6	54
144	Efficacy of internal cardioversion for chronic atrial fibrillation in patients with and without left ventricular dysfunction. International Journal of Cardiology, 2004, 95, 43-47.	1.7	10

#	Article	IF	Citations
145	Cardiac resynchronization by pacing: an electrical treatment of heart failure. International Journal of Cardiology, 2004, 94, 151-161.	1.7	40
146	Surgical Treatment of Degenerative Mitral Regurgitation: Should We Approach Differently Patients with Flail Leaflets of Simple Mitral Valve Prolapse?., 2004, 41, 95-107.		2
147	Combined heart and liver transplantation for familial amyloidotic neuropathy: Considerations from the hepatic point of view. Liver Transplantation, 2003, 9, 986-992.	2.4	46
148	Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. American Journal of Cardiology, 2003, 91, 97-99.	1.6	103
149	Qrs interval time-related changes and prognosis in heart failure. American Journal of Cardiology, 2003, 91, 514.	1.6	4
150	Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. American Heart Journal, 2003, 146, 298-303.	2.7	34
151	Distance between Patients' Subjective Perceptions and Objectively Evaluated Disease Severity in Chronic Heart Failure. Psychotherapy and Psychosomatics, 2003, 72, 166-170.	8.8	32
152	Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. European Journal of Heart Failure, 2003, 5, 419-425.	7.1	28
153	Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation, 2003, 75, 839-843.	1.0	59
154	Hospitalization for congestive heart failure: is it still a cardiology business?. European Journal of Heart Failure, 2002, 4, 99-104.	7.1	19
155	Atrial fibrillation complicating the course of degenerative mitral regurgitation. Journal of the American College of Cardiology, 2002, 40, 84-92.	2.8	341
156	Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. Journal of Heart and Lung Transplantation, 2002, 21, 899-901.	0.6	54
157	Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease. Clinical Nutrition, 2002, 21, 245-248.	5.0	5
158	Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C→T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. Journal of Heart and Lung Transplantation, 2001, 20, 1245-1251.	0.6	9
159	Ischemic Mitral Regurgitation. Circulation, 2001, 103, 1759-1764.	1.6	1,306
160	Sudden death in mitral regurgitation due to flail leaflet. Journal of the American College of Cardiology, 1999, 34, 2078-2085.	2.8	272
161	Percutaneous Mechanical Circulatory Support Devices: Systems and Clinical Options. , 0, , .		0